RedHill Biopharma announces last patient out for phase 2/3 COVID-19 study of oral Opaganib
Top-line results expected in the coming weeksCredit: RedHill Biopharma TEL AVIV, Israel and RALEIGH, NC, July 19, 2021, RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or...
















